Roth Capital initiates coverage on Immune Pharmaceuticals (NASDAQ: IMNP) with a Buy rating and a price target of $6.00.Analyst Joseph ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE